Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN D VICUNA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1275755670
CMS profile
148305
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$15,428.49

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $11,196.88 9
Food and Beverage $3,349.49 155
Long term medical supply or device loan $482.13 5
Honoraria $300.00 1
Education $99.99 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $4,355.66 12
AstraZeneca Pharmaceuticals LP $4,215.72 10
Incyte Corporation $1,155.72 5
Janssen Scientific Affairs, LLC $1,100.32 2
Bayer Healthcare Pharmaceuticals Inc. $919.48 2
Novartis Pharmaceuticals Corporation $723.96 16
Chiesi USA, Inc. $300.00 1
Daiichi Sankyo Inc. $240.70 18
SOBI, INC $194.18 6
Janssen Biotech, Inc. $183.01 11
Alexion Pharmaceuticals, Inc. $182.28 4
EMD Serono, Inc. $165.24 7
Sirtex Medical Inc $145.70 1
Tempus AI, Inc $139.94 10
PFIZER INC. $123.53 10
Astellas Pharma US Inc $109.04 4
Gilead Sciences, Inc. $90.10 4
Agios Pharmaceuticals, Inc. $88.77 3
Celgene Corporation $86.58 4
Merck Sharp & Dohme LLC $58.60 2
Karyopharm Therapeutics Inc. $57.63 2
ARRAY BIOPHARMA INC $56.80 4
Genentech, Inc. $45.59 1
Sumitomo Pharma America, Inc. $45.00 2
Lilly USA, LLC $42.84 2
Genmab U.S., Inc. $42.43 2
Takeda Pharmaceuticals U.S.A., Inc. $42.35 2
Alnylam Pharmaceuticals Inc. $42.18 2
Genentech USA, Inc. $39.72 2
Boehringer Ingelheim Pharmaceuticals, Inc. $35.68 2
Regeneron Healthcare Solutions, Inc. $35.35 2
Syndax Pharmaceuticals, Inc. $30.70 1
Legend Biotech USA Inc. $29.76 1
GENZYME CORPORATION $29.06 1
Dendreon Pharmaceuticals LLC $27.06 1
SUN PHARMACEUTICAL INDUSTRIES INC. $25.63 1
Verity Pharmaceuticals Inc. $23.84 1
Exelixis Inc. $23.73 1
X4 Pharmaceuticals, Inc. $23.57 1
Aveo Pharmaceuticals, Inc. $20.00 1
Eisai Inc. $18.90 1
Aadi Bioscience, Inc. $17.97 1
Ipsen Biopharmaceuticals, Inc $17.85 1
ADC THERAPEUTICS AMERICA, INC. $16.65 1
GlaxoSmithKline, LLC. $15.58 1
BeOne Medicines USA, Inc. $15.21 1
SpringWorks Therapeutics, Inc. $14.80 1
Adaptive Biotechnologies Corporation $14.08 1

Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN D VICUNA

NPI 1275755670 · CMS profile ID 148305

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275755670?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN D VICUNA, NPI 1275755670, CMS profile ID 148305. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275755670?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BRIAN D VICUNA, NPI 1275755670, CMS profile ID 148305. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275755670?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BRIAN D VICUNA, NPI 1275755670, CMS profile ID 148305, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1275755670?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $15,428.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $15.3409/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234570148 CMS
Janssen Biotech, Inc. $20.9509/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175269102 CMS
Tempus AI, Inc $19.3609/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250352998 CMS
GENZYME CORPORATION $29.0609/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233396158 CMS
ABBVIE INC. $296.8808/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1204644324 CMS
ABBVIE INC. $22.2208/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204644320 CMS
Tempus AI, Inc $8.6708/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250352996 CMS
Daiichi Sankyo Inc. $21.8708/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197014303 CMS
Genentech, Inc. $45.5908/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211499633 CMS
Merck Sharp & Dohme LLC $27.3608/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238139369 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5608/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223014536 CMS
Gilead Sciences, Inc. $33.7808/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234420980 CMS
Astellas Pharma US Inc $19.0108/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238679609 CMS
PFIZER INC. $22.0008/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229026977 CMS
Alnylam Pharmaceuticals Inc. $23.1308/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212737665 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.5908/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223893233 CMS
AstraZeneca Pharmaceuticals LP $32.0907/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206990641 CMS
Genmab U.S., Inc. $21.0907/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235918596 CMS
Tempus AI, Inc $5.5807/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250352994 CMS
ARRAY BIOPHARMA INC $20.0207/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230019604 CMS
PFIZER INC. $19.9807/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229104129 CMS
ABBVIE INC. $24.6807/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204644317 CMS
AstraZeneca Pharmaceuticals LP $19.1107/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206310902 CMS
SOBI, INC $18.7907/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240241455 CMS
Daiichi Sankyo Inc. $13.6307/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197087057 CMS
Genentech USA, Inc. $16.1207/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211499635 CMS
Novartis Pharmaceuticals Corporation $28.6307/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200533722 CMS
Genmab U.S., Inc. $21.3407/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235918594 CMS
Celgene Corporation $14.7007/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184939843 CMS
Novartis Pharmaceuticals Corporation $16.7907/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200533734 CMS
EMD Serono, Inc. $27.2507/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236906595 CMS
EMD Serono, Inc. $0.9007/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236921635 CMS
Astellas Pharma US Inc $29.3306/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238640406 CMS
Daiichi Sankyo Inc. $15.0506/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197079483 CMS
AstraZeneca Pharmaceuticals LP $22.5206/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207225996 CMS
ABBVIE INC. $26.2406/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204644312 CMS
Ipsen Biopharmaceuticals, Inc $17.8506/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208833622 CMS
ARRAY BIOPHARMA INC $2.3006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228943263 CMS
Agios Pharmaceuticals, Inc. $33.1206/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253247599 CMS
AstraZeneca Pharmaceuticals LP $1,675.0006/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206138444 CMS
Legend Biotech USA Inc. $29.7605/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236478770 CMS
Tempus AI, Inc $15.4405/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250352992 CMS
Genentech USA, Inc. $23.6005/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211499631 CMS
Novartis Pharmaceuticals Corporation $37.3305/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200533708 CMS
Alexion Pharmaceuticals, Inc. $106.3105/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202985274 CMS
Daiichi Sankyo Inc. $5.4705/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197070727 CMS
Karyopharm Therapeutics Inc. $32.3705/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246643174 CMS
SOBI, INC $15.0905/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240241445 CMS
EMD Serono, Inc. $9.9105/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236875401 CMS
Janssen Biotech, Inc. $5.5805/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175276521 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,601.46 102
PY2020 $12,155.54 74
PY2021 $22,220.24 100
PY2022 $23,827.02 106
PY2023 $9,439.46 161
PY2024 $20,699.23 183
PY2025 $15,428.49 172

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $65,352.83 64
PY2024 Recipient $288.58 1
PY2024 Principal investigator $132,363.23 64
PY2023 Principal investigator $212,383.75 43
PY2022 Principal investigator $211,645.28 56
PY2021 Recipient $717.51 1
PY2021 Principal investigator $318,946.14 44
PY2020 Principal investigator $79,072.03 17
PY2019 Principal investigator $145,014.56 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA ALLISON CURTIS KINGSLEY MEOZ MICHAEL + SANCHEZ PROF CORP
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211590336
Principal investigator 1 GlaxoSmithKline, LLC. $601.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187243
Principal investigator 1 GlaxoSmithKline, LLC. $601.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187247
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187252
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187256
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187260
Principal investigator 1 GlaxoSmithKline, LLC. $75.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187265
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187269
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192188062
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192188066
Principal investigator 1 GlaxoSmithKline, LLC. $601.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192188071
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182741
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182743
Principal investigator 1 Astellas Pharma Global Development $558.60 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182745
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182747
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182749
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182751
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182753
Principal investigator 1 Genentech, Inc. $2,500.00 08/26/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA ALLISON CURTIS KINGSLEY MEOZ MICHAEL + SANCHEZ PROF CORP
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211590328
Principal investigator 1 Exelixis Inc. $6,030.00 08/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386564
Principal investigator 1 Genentech, Inc. $200.00 08/01/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA ALLISON CURTIS KINGSLEY MEOZ MICHAEL + SANCHEZ PROF CORP
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211590324
Principal investigator 1 Exelixis Inc. $200.00 07/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386550
Principal investigator 1 Genentech, Inc. $200.00 07/02/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA ALLISON CURTIS KINGSLEY MEOZ MICHAEL + SANCHEZ PROF CORP
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211590332
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182671
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182673
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182675
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182677
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182679
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182681
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182683
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182685
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182687
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182689
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182691
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182693
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182695
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182697
Principal investigator 1 Astellas Pharma Global Development $1,500.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182699
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182701
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182703
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182705
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182707
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182709
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182711
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182713
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182715
Principal investigator 1 Astellas Pharma Global Development $450.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182717
Principal investigator 1 Astellas Pharma Global Development $150.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182719
Principal investigator 1 Astellas Pharma Global Development $150.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182721
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182723
Principal investigator 1 Astellas Pharma Global Development $150.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182725
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182727
Principal investigator 1 Astellas Pharma Global Development $600.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182729
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182731
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182733
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182735
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182737
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182739
Principal investigator 1 Ipsen Bioscience Inc. $24,665.13 04/08/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545753
Principal investigator 1 Genentech, Inc. $454.00 04/02/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211675721
Principal investigator 1 Genentech, Inc. $1,567.00 03/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211675724
Principal investigator 1 Ipsen Bioscience Inc. $650.00 01/27/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545747
Principal investigator 1 Ipsen Bioscience Inc. $200.00 01/27/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545749
Principal investigator 1 Ipsen Bioscience Inc. $200.00 01/27/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545751